IP Verse

Apixaban Formulations - EP3781132

The patent EP3781132 was granted to Bristol Myers Squibb on Mar 20, 2024. The application was originally filed on Apr 15, 2019 under application number EP19722333A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3781132

BRISTOL MYERS SQUIBB
Application Number
EP19722333A
Filing Date
Apr 15, 2019
Status
Granted And Under Opposition
Feb 16, 2024
Grant Date
Mar 20, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STADA ARZNEIMITTELDec 19, 2024KERNEBECKADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2012087978
DESCRIPTIONUS2013045245
DESCRIPTIONUS6967208
INTERNATIONAL-SEARCH-REPORTCN105663049
INTERNATIONAL-SEARCH-REPORTCN106913528
INTERNATIONAL-SEARCH-REPORTWO2014027334
OPPOSITIONWO2010003641
OPPOSITIONWO2011106478
OPPOSITIONWO2014052678

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "Eliquis 2.5 mg film-coated tablets", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, European Medicines Agency, (20160114), pages 1 - 82, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, URL: https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis, XP093252396-
OPPOSITION- Anonymous, "Suglets® PF010 Sugar Spheres ", Technical Bulletin, Colorcon, BPSI Holdings, LLC, (20130101), pages 1 - 2, Technical Bulletin, URL: https://notox.colorcon.com/item/2108-tech-bulletin-suglets, XP093254534-
OPPOSITION- Anonymous, "Techncial Brief Sprinkle Capsules", Techncial Brief, Lonza EMEA, (20170101), pages 1 - 2, Techncial Brief , URL: https://go2.lonza.com/rs/552-NMO-481/images/Sprinkle%20capsules%20-%20factsheet.pdf, XP093254511-
OPPOSITION- Anonymous, "Xarelto 2.5 mg film-coated tablets ", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, European Medicines Agency, (20180522), pages 1 - 312, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, URL: https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto, XP093252362-
OPPOSITION- Bayer (responsible Party), "Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates (Einstein Jr)", ClinicalTrials.gov, NLM, (20180207), pages 1 - 14, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT02564718?cond=Rivaroxaban%20for%20Treatment%20in%20Venous%20or%20Arterial%20Thrombosis%20in%20Neonates&rank=1&tab=history&a=29#version-content-panel, XP093254541-
OPPOSITION- D19 - Affidavit Sherif Badawy 2025-
OPPOSITION- D20 - Overview Auxiliary requests-
OPPOSITION- De La Hoz P. Leonardo , "TECHNICAL DATA SHEET FOR EMPTY HARD GELATIN CAPSULES", TECHNICAL DATA SHEET, CapsCanada, (20180101), pages 1 - 8, TECHNICAL DATA SHEET , URL: https://www.gocaps.com/wp-content/uploads/2021/04/G-Caps-G-Caps_Technical-Data-SheetPR00373600.pdf, XP093254539-
OPPOSITION- MARTINEZ L, ET AL., "ACTIVE LAYERING AND DIRECT COMPRESSION OF SUGAR SPHERES: CONTENT HOMOGENEITY IN LOW-DOSAGE TABLETS", PHARMACEUTICAL TECHNOLOGY INTERNATIONAL., INGLEWOOD, CA., US, US , (20011001), vol. 13, no. 10, ISSN 0164-6826, page 38 + 40 42 + 44 + 46, XP009050684-
OPPOSITION- Moreton R C, "Sugar Spheres", Moreton R C, Rowe Raymond C., Handbook of Pharmaceutical Excipients, Pharmaceutical Press , (20021007), pages 630 - 631, ISBN 978-0-85369-472-4, XP093254527-
OPPOSITION- Tschopp Philippe, "Starter pellets: Materials, Manufacturing Methods, and Applications", Tablets & Capsules, CSC Publishing, (20150701), pages 1 - 4, Tablets & Capsules, URL: https://www.pharmaexcipients.com/wp-content/uploads/2021/12/Starter-pellets-Materials-manufacturing-methods-and-applications.pdf, XP093254535-
OPPOSITION- Werner Detlef, "Sugar spheres: a versatile excipient for oral pellet medications with modified release kinetics", PHARMACEUTICAL TECHNOLOGY INTERNATIONAL., INGLEWOOD, CA., US, US , (20060104), vol. 18, no. 4, ISSN 0164-6826, pages 1 - 4, XP093252366-
OPPOSITION- Wroblewski Tanya M, "NDA Approval: Eliquis Sprinkle", NDA Approval, FDA, pages 1 - 5, NDA Approval, URL: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/220073Orig1s000ltr.pdf, XP093279951-
OPPOSITION- Richard Sidwell, Jason Hansell, Manish Rane, and Ali R. Rajabi-Siahboomi, "Chapter 2 Characterization of Inert Cores for Multiparticulate Dosage Forms", Multiparticulate Drug Delivery - Formulation, Processing and Manufacturing, SPRINGER, (20170528), pages 5 - 35, doi:10.1007/978-1-4939-7012-4_2, ISBN 978-1-4939-7010-0, XP009559580
OPPOSITION- Von Vajna Erika, Alam Ruhaniyah, So Tsz-Yin, "Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population", Cardiology and Therapy, (20160601), vol. 5, no. 1, doi:10.1007/s40119-015-0054-y, ISSN 2193-8261, pages 19 - 41, XP093252364
OPPOSITION- Majee Sutapa Biswas, Avlani Dhruti, Biswas Gopa Roy, "HPMC AS CAPSULE SHELL MATERIAL: PHYSICOCHEMICAL, PHARMACEUTICAL AND BIOPHARMACEUTICAL PROPERTIES", International journal of pharmacy and pharmaceutical sciences, India, India, (20171001), vol. 9, no. 10, doi:10.22159/ijpps.2017v9i10.20707, ISSN 0975-1491, pages 1 - 6, XP093252483

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents